Perceive Biotherapeutics Closes $78M in Series B Funding
- Perceive Biotherapeutics, a San Francisco, CA-based biotech company focused on technologies and therapeutics in ophthalmology, raised $78M in Series B funding
- The round was led by Johnson & Johnson Innovation – JJDC, Inc.(JJDC), with participation from Deerfield Management, Braidwell LP, the Retinal Degeneration Fund, and Catalio Capital Management, LP
- The company intends to use the funds to accelerate its progress as it drives lead AMD program into the clinic and continues development progress across extensive ophthalmology pipeline
- PerceiveBiotherapeutics is advancing a deep and diversified pipeline of targets and treatment modalities in multiple therapeutic verticals, with lead pipeline programs in ophthalmology
- Perceive Bio is advancing therapeutic programs in geographic atrophy / age-related macular degeneration, glaucoma, and additional undisclosed disease areas
